We recommend viewing the videos in the latest Google Chrome browser.
You can submit your questions via the E-ASK interface at the bottom of the website.
Program
17:15 - 17:30
Welcome
17:30 - 18:00
Challenges in CKD anaemia management / Univ.-Prof. Dr. Danilo Fliser (Germany)
18:00 - 18:15
Q&A
18:15 - 18:45
New perspectives of CKD anaemia management with HIF PHIs / Prof David Wheeler MBChB, MD, FRCP (UK)
18:45 - 19:00
Q&A
PRESENTERS
Prof. Danilo Fliser
(Germany)
Since 2007, Dr. Fliser is Professor of Internal Medicine, Head of the Department of Internal Medicine IV (Renal & Hypertensive Disease) and Spokesman of the Transplant Centre at the Saarland University Medical Centre in Homburg/Saar, Germany.
Dr. Fliser´s current research interests are progression of chronic kidney disease, vascular biology, and cardiovascular complications in patients with chronic kidney disease. He has authored more than 375 original publications (PubMed), and his current Hirsch Factor is 88. He seves on the editorial board of several nephrology journals, including Der Nephrologe (Managing Editor), JASN, Kidney International and NDT (Theme Editor). He is member of the Steering Committee of CKDOPPS and contributed to the KDIGO guidelines as well as to the ERBP.
From 2015 to 2018 Dr. Fliser served in the ERA Council as an Ordinary Council Member, and from 2016 to 2019 as the Chair of the Paper Selection Committee for the annual ERA congresses. He was Chair of the Scientific Committee of the 53rd ERA annual congress in Vienna in 2016. Finally, Dr. Fliser was appointed as the ERA Renal Science Chair for the period 2018-2025.
Prof. David Wheeler
(UK)
Professor of Kidney Medicine at University College London, UK and Honorary Consultant Nephrologist at the Royal Free London NHS Foundation Trust.
He has more than 20 years clinical experience in the field of nephrology with more than 200 publications. He is a clinician scientist interested in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure.
He has participated in the development and running of several large-scale clinical trials testing lipid lowering regimens, calcimimetics, SGLT2 inhibitors and HIF stabilisers in patients chronic kidney disease.
Past President of the UK Renal Association and past chair of UK Renal Registry. KDIGO co-chair between 2012 and 2019. Associate Editor of Nephrology Dialysis Transplantation (NDT). He has been involved in the development of Clinical Practice Guidelines for several organisations (e.g. KDIGO).
He served as co-chair of KDIGO Controversies Conference on Novel Anemia Therapies in CKD in 2021.
E-ASK
Ask from speakers during the livestream
Contact information for Safety reporting:
Hungary: Drugsafety.hu@astellas.com
Bulgaria: pharmacovigilance_bg@astellas.com
Romania: Farmacovigilenta.ro@astellas.com
Contact information for Medical Enquiries: medinfo.HBR@astellas.com
Contact details of Astellas:
Astellas Pharma Kft.: 1124 Budapest, Csörsz u. 43., Tel.: (1) 577 8200, Fax: (1) 577 8210
Astellas Pharma EOOD: 90 Tsarigradsko shose Blvd., 1784 Sofia, Bulgaria, Tel.: +359 2 862 53 72, Fax: +359 2 862 53 77
Astellas Pharma S.R.L.: Complexul One United Tower; Calea Floreasca, nr. 165, et.12,
Sector 1, București, Tel: 0040213610495, Fax: 0040213610496
This non-promotional meeting has been fully funded and organized by Astellas and is intended for healthcare professionals only.
Astellas is committed to protecting your personal information and will only use it in accordance
with the applicable data privacy law and our Astellas Privacy Notice. For further information on how we process
and protect your personal information and how you may exercise your data protection rights, please refer
to our privacy notice at: https://www.astellas.com/eu/privacy-notice-online-resources/.
If you have any further questions please contact us at privacy@astellas.com
Document number: NEPH_2022_0007_HBR
Closure date: 04.03.2022
Expiry date: 18.03.2022